SHINGLES
Clinical trials for SHINGLES explained in plain language.
Never miss a new study
Get alerted when new SHINGLES trials appear
Sign up with your email to follow new studies for SHINGLES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shingles vaccine Z-1018 takes on shingrix in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called Z-1018 in about 764 healthy adults aged 50 and older. It compares Z-1018 to the current vaccine, Shingrix, to see if it is safe and triggers a strong immune response. The trial is in early phases (1 and 2), so the main focus is on sa…
Matched conditions: SHINGLES
Phase: PHASE1, PHASE2 • Sponsor: Dynavax Technologies Corporation • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New shingles vaccine shows promise in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix,…
Matched conditions: SHINGLES
Phase: PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New shingles vaccine candidate enters Mid-Stage trial
⭐️ VACCINE ⭐️ OngoingThis study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.
Matched conditions: SHINGLES
Phase: PHASE2 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:07 UTC
-
New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
⭐️ VACCINE ⭐️ OngoingThis phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Matched conditions: SHINGLES
Phase: PHASE2 • Sponsor: Curevo Inc • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:53 UTC